JPH01151581A - ピリミド［４，５−ｇ］キノリンおよびその製造中間体 - Google Patents

ピリミド［４，５−ｇ］キノリンおよびその製造中間体

Info

Publication number
JPH01151581A
JPH01151581A JP63289902A JP28990288A JPH01151581A JP H01151581 A JPH01151581 A JP H01151581A JP 63289902 A JP63289902 A JP 63289902A JP 28990288 A JP28990288 A JP 28990288A JP H01151581 A JPH01151581 A JP H01151581A
Authority
JP
Japan
Prior art keywords
trans
propyl
formula
quinoline
octahydropyrimide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP63289902A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0529398B2 (enExample
Inventor
Cynthia L Nichols
シンチア・エル・ニコルス
Edmund C Kornfeld
エドマンド・シー・コーンフェルド
Mark M Foreman
マーク・エム・フォアマン
John M Schaus
ジョン・エム・シャウス
Diane L Huser
ダイアン・エル・ヒューザー
Richard N Booher
リチャード・エヌ・ブーエル
T Wong David
ダビッド・ティー・ウォング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/535,503 external-priority patent/US4501890A/en
Priority claimed from US06/535,474 external-priority patent/US4521421A/en
Priority claimed from US06/575,126 external-priority patent/US4528290A/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JPH01151581A publication Critical patent/JPH01151581A/ja
Publication of JPH0529398B2 publication Critical patent/JPH0529398B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP63289902A 1983-09-26 1988-11-15 ピリミド［４，５−ｇ］キノリンおよびその製造中間体 Granted JPH01151581A (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US53551983A 1983-09-26 1983-09-26
US535474 1983-09-26
US535519 1983-09-26
US06/535,503 US4501890A (en) 1983-09-26 1983-09-26 Trans-(±)-2,4,6-substituted-5,5a,6,7,8,9,9a,10-octahydro-pyrimido[4,5-g]quinolines
US06/535,474 US4521421A (en) 1983-09-26 1983-09-26 Treatment of sexual dysfunction
US535503 1983-09-26
US575126 1984-01-30
US06/575,126 US4528290A (en) 1984-01-30 1984-01-30 Stimulating dopamine D-1 receptors
US60609184A 1984-05-02 1984-05-02
US606091 1984-05-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP59177383A Division JPS6072891A (ja) 1983-09-26 1984-08-24 ピリミド〔４，５−ｇ〕キノリンおよびその製造中間体

Publications (2)

Publication Number Publication Date
JPH01151581A true JPH01151581A (ja) 1989-06-14
JPH0529398B2 JPH0529398B2 (enExample) 1993-04-30

Family

ID=27541855

Family Applications (1)

Application Number Title Priority Date Filing Date
JP63289902A Granted JPH01151581A (ja) 1983-09-26 1988-11-15 ピリミド［４，５−ｇ］キノリンおよびその製造中間体

Country Status (16)

Country Link
EP (1) EP0139393B1 (enExample)
JP (1) JPH01151581A (enExample)
AU (2) AU569539B2 (enExample)
CY (1) CY1495A (enExample)
DE (1) DE3484583D1 (enExample)
DK (4) DK164867C (enExample)
FI (1) FI78091C (enExample)
GB (1) GB2146985B (enExample)
GR (1) GR80201B (enExample)
HK (1) HK98789A (enExample)
IE (1) IE57848B1 (enExample)
IL (1) IL72730A (enExample)
NZ (1) NZ209295A (enExample)
PT (1) PT79112B (enExample)
RO (1) RO89126A (enExample)
SG (1) SG46389G (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK349385A (da) * 1984-08-03 1986-02-04 Lilly Co Eli Fremgangsmaade til fremstilling af tricycliske quinolin-derivater og mellemprodukt til brug ved fremgangsmaaden
US4764609A (en) * 1986-03-31 1988-08-16 Eli Lilly And Company Synthesis of 2-aminopyrimido[4,5-g]quinolines
US4826986A (en) * 1986-06-16 1989-05-02 Eli Lilly And Company 6-Oxo-trans-octa- and decahydroquinolines
US4762843A (en) * 1986-09-15 1988-08-09 Warner-Lambert Company Hetero [f] fused carbocyclic pyridines as dopaminergic agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59202892A (ja) * 1983-05-04 1984-11-16 Ricoh Co Ltd 光学的情報記録媒体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4198415A (en) * 1979-01-22 1980-04-15 Eli Lilly And Company Prolactin inhibiting octahydro pyrazolo[3,4-g]quinolines
US4507478A (en) * 1983-09-26 1985-03-26 Eli Lilly And Company 2-Mercaptopyrimidohexahydroquinolines and related compounds
DK349385A (da) * 1984-08-03 1986-02-04 Lilly Co Eli Fremgangsmaade til fremstilling af tricycliske quinolin-derivater og mellemprodukt til brug ved fremgangsmaaden

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59202892A (ja) * 1983-05-04 1984-11-16 Ricoh Co Ltd 光学的情報記録媒体

Also Published As

Publication number Publication date
HK98789A (en) 1989-12-22
DK296390A (da) 1990-12-13
DK296290D0 (da) 1990-12-13
DK169622B1 (da) 1994-12-27
IL72730A0 (en) 1984-11-30
NZ209295A (en) 1987-05-29
AU585473B2 (en) 1989-06-15
EP0139393A3 (en) 1988-01-13
DK296190A (da) 1990-12-13
GR80201B (en) 1985-01-02
GB2146985A (en) 1985-05-01
PT79112B (en) 1986-11-14
DK296290A (da) 1990-12-13
IL72730A (en) 1987-10-30
DK296390D0 (da) 1990-12-13
DK296190D0 (da) 1990-12-13
GB2146985B (en) 1987-05-28
EP0139393B1 (en) 1991-05-15
FI78091C (fi) 1989-06-12
SG46389G (en) 1989-12-22
CY1495A (en) 1990-02-16
FI843282A7 (fi) 1985-03-27
AU8216887A (en) 1988-03-31
DE3484583D1 (de) 1991-06-20
IE842154L (en) 1985-03-26
IE57848B1 (en) 1993-04-21
DK164867C (da) 1993-11-08
DK169970B1 (da) 1995-04-18
GB8421160D0 (en) 1984-09-26
PT79112A (en) 1984-09-01
FI843282A0 (fi) 1984-08-20
AU569539B2 (en) 1988-02-04
FI78091B (fi) 1989-02-28
DK169948B1 (da) 1995-04-10
DK164867B (da) 1992-08-31
JPH0529398B2 (enExample) 1993-04-30
AU3228084A (en) 1985-04-04
DK400984D0 (da) 1984-08-22
RO89126A (ro) 1986-04-30
DK400984A (da) 1985-03-27
EP0139393A2 (en) 1985-05-02

Similar Documents

Publication Publication Date Title
JPH0528236B2 (enExample)
US4501890A (en) Trans-(±)-2,4,6-substituted-5,5a,6,7,8,9,9a,10-octahydro-pyrimido[4,5-g]quinolines
CS247073B2 (en) Production method of 2-substituted 4-amino-6,7-dimethoxyghinolins
TW200306837A (en) Adenosine A2a receptor antagonists
JPH05194527A (ja) ピラゾール環がアルキル化されたピラゾロキノリン類の製造中間体
US4537893A (en) Octahydrothiazolo[4,5-g]quinolines and use as prolactin secretion inhibitors
US4659832A (en) Process for the preparation of octahydro-oxazolo [4,5-G]quinolines
JPH01151581A (ja) ピリミド［４，５−ｇ］キノリンおよびその製造中間体
JPS62473A (ja) ジアルキルアミノテトラヒドロベンゾチアゾ−ルおよびオキサゾ−ル
EP0172697B1 (en) Octahydro-oxazolo[4,5-g]quinolines
US4528290A (en) Stimulating dopamine D-1 receptors
US4599339A (en) Use of pyrimido[4,5-g]quinolines in treating parkinsonism
KR880001454B1 (ko) 피리미도[4,5-g]퀴놀린 유도체
US4596871A (en) Pyrazole-ring alkylated pyrazoloquinolines
CA1234112A (en) Pyrimido(4,5-g)quinolines and intermediates
EP0111990B1 (en) Hypotensive agents
US4622398A (en) Dialkylaminotetrahydroquinazoline
US4698347A (en) Octahydro-oxazolo[4,5-g]quinolines derivatives and decahydro quinoline intermediates and their use as dopamine D-2 agonists
CA1249277A (en) Hypotensive agents
HU199462B (en) Process for producing pyrimido/4,5-a/quinoline derivatives and pharmaceutical compositions comprising same